Vanta Bioscience Ltd
BSE:540729
Vanta Bioscience Ltd
BSE:540729
Price:
18.22
INR
19.87%
Market Closed
Market Cap:
₹129.5m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Vanta Bioscience Ltd
BSE:540729
|
IN |
|
L
|
Ladun Investment Company SCJSC
SAU:9535
|
SA |
|
S
|
SA Corporate Real Estate Fund Managers (Pty) Ltd
JSE:SAC
|
ZA |
|
E
|
EVI Industries Inc
AMEX:EVI
|
US |
|
S
|
Sino Splendid Holdings Ltd
HKEX:8006
|
HK |
|
Nongshim Co Ltd
KRX:004370
|
KR |
Balance Sheet
Balance Sheet Decomposition
Vanta Bioscience Ltd
Vanta Bioscience Ltd
Balance Sheet Decomposition is not available for
Vanta Bioscience Ltd
Vanta Bioscience Ltd
Balance Sheet
Vanta Bioscience Ltd
Vanta Bioscience Ltd
Currency: INR
| Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
4
|
1
|
33
|
2
|
27
|
2
|
1
|
2
|
2
|
|
| Cash |
4
|
1
|
33
|
2
|
27
|
2
|
1
|
2
|
2
|
|
| Short-Term Investments |
0
|
45
|
20
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
9
|
24
|
37
|
60
|
63
|
73
|
89
|
81
|
|
| Accounts Receivables |
0
|
3
|
16
|
14
|
20
|
11
|
20
|
31
|
25
|
|
| Other Receivables |
0
|
5
|
8
|
23
|
40
|
52
|
54
|
58
|
56
|
|
| Inventory |
0
|
30
|
92
|
140
|
98
|
72
|
72
|
75
|
65
|
|
| Other Current Assets |
0
|
5
|
1
|
19
|
15
|
7
|
7
|
6
|
5
|
|
| Total Current Assets |
5
|
90
|
171
|
198
|
199
|
145
|
152
|
172
|
154
|
|
| PP&E Net |
130
|
150
|
167
|
229
|
349
|
373
|
332
|
284
|
240
|
|
| PP&E Gross |
0
|
0
|
0
|
229
|
349
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
25
|
37
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
0
|
49
|
49
|
49
|
139
|
216
|
240
|
257
|
315
|
|
| Note Receivable |
3
|
0
|
0
|
5
|
5
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
1
|
4
|
4
|
5
|
5
|
80
|
122
|
141
|
150
|
|
| Total Assets |
138
N/A
|
292
+112%
|
390
+34%
|
486
+25%
|
696
+43%
|
814
+17%
|
847
+4%
|
854
+1%
|
859
+1%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
0
|
2
|
5
|
5
|
5
|
25
|
42
|
56
|
49
|
|
| Accrued Liabilities |
0
|
0
|
1
|
4
|
9
|
0
|
0
|
0
|
0
|
|
| Short-Term Debt |
0
|
12
|
0
|
19
|
0
|
0
|
37
|
48
|
78
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
11
|
18
|
81
|
79
|
64
|
73
|
82
|
|
| Other Current Liabilities |
1
|
10
|
15
|
53
|
54
|
39
|
34
|
52
|
57
|
|
| Total Current Liabilities |
1
|
24
|
32
|
99
|
148
|
143
|
177
|
229
|
266
|
|
| Long-Term Debt |
75
|
100
|
122
|
137
|
278
|
370
|
471
|
488
|
541
|
|
| Deferred Income Tax |
0
|
2
|
4
|
6
|
7
|
8
|
10
|
7
|
14
|
|
| Minority Interest |
0
|
0
|
10
|
10
|
23
|
53
|
14
|
22
|
66
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
76
N/A
|
126
+66%
|
168
+33%
|
251
+50%
|
457
+82%
|
574
+26%
|
672
+17%
|
702
+4%
|
755
+7%
|
|
| Equity | ||||||||||
| Common Stock |
37
|
57
|
63
|
63
|
63
|
63
|
63
|
63
|
63
|
|
| Retained Earnings |
0
|
109
|
7
|
19
|
24
|
177
|
112
|
89
|
41
|
|
| Additional Paid In Capital |
25
|
0
|
152
|
152
|
152
|
0
|
0
|
0
|
0
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
62
N/A
|
166
+170%
|
222
+34%
|
235
+5%
|
239
+2%
|
240
+0%
|
175
-27%
|
152
-13%
|
104
-31%
|
|
| Total Liabilities & Equity |
138
N/A
|
292
+112%
|
390
+34%
|
486
+25%
|
696
+43%
|
814
+17%
|
847
+4%
|
854
+1%
|
859
+1%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
6
|
6
|
6
|
6
|
6
|
6
|
6
|
6
|
6
|
|
Switch to:
Switch to:
See Also
Discover More
